Gut microbial dysbiosis has been linked to metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes. However, the specific metabolic effects of candidate probiotic strains across the spectrum of these diseases are not fully established. Based on validation of disease-associated microbial patterns in a clinical cohort, the authors selected Lactobacillus acidophilus as a candidate probiotic and performed systematic investigations across multiple complementary preclinical models.
The study evaluated the effects of L. acidophilus supplementation in several mouse models that represent diet- and genetically driven metabolic disease. Models described in the abstract include mice fed a Western diet, a fructose-palmitate-cholesterol diet, a high-fat diet, and leptin-deficient ob/ob mice. These complementary models were used to assess hepatic outcomes, systemic glucose metabolism, molecular signaling, and gut microbial community structure.
The abstract does not report specific experimental parameters such as probiotic dose, route or frequency of administration, treatment duration, or sample sizes; those details were not reported in the abstract.
Across multiple models, L. acidophilus supplementation attenuated hepatic steatosis and reduced inflammatory liver injury. The observed histologic and biochemical improvements in the liver were consistent across different diet-induced and genetic models, indicating effects on both lipid accumulation and inflammation.
Reduction in inflammatory injury was accompanied by decreased hepatic expression of pro-inflammatory cytokines, suggesting that the probiotic intervention modulated hepatic inflammatory signaling in addition to lipid handling.
At the molecular level, L. acidophilus influenced pathways implicated in energy sensing and metabolic regulation. The abstract reports changes in AMPK-associated signaling, which is central to cellular energy homeostasis. Gene expression alterations included decreased expression of lipogenic genes such as Srebf1 and Acc, and decreased expression of gluconeogenic genes including Pepck and G6pc. By contrast, expression of Ppara was increased, consistent with enhanced fatty acid oxidation and shifts away from lipogenesis.
Transcriptomic profiling indicated broader modulation of hepatic metabolic networks beyond these canonical genes. Altered expression of Lpin1 and enrichment of pathways related to nutrient sensing and metabolic regulation were observed, suggesting coordinated changes in multiple metabolic axes.
In leptin-deficient ob/ob mice, L. acidophilus supplementation improved glucose tolerance. The abstract links improvements in glucose handling to the observed hepatic gene expression changes — notably decreased gluconeogenic gene expression — and to alterations in AMPK-associated signaling. Specific metrics of glucose tolerance (for example glucose tolerance test values, insulin levels, or HOMA-IR) are not provided in the abstract.
Supplementation with L. acidophilus altered gut microbial community structure in the mouse models used. While the abstract confirms microbiome shifts, it does not enumerate specific taxa changes or effect sizes in mice beyond noting community-level alterations.
Analyses from a human clinical cohort revealed context-dependent microbial patterns across metabolic disease states. The abstract highlights associations involving Lactobacillus, Akkermansia, and butyrate-producing Firmicutes when comparing microbial patterns across MASLD and diabetes. These human findings supported the selection of L. acidophilus for preclinical testing, but detailed cohort characteristics, statistical measures, and the directionality or magnitude of the associations are not specified in the abstract.
Collectively, the preclinical and human cohort data reported in the abstract suggest that Lactobacillus acidophilus may improve metabolic dysfunction in MASLD and diabetes through two complementary mechanisms: coordinated regulation of hepatic glucose and lipid metabolism (including modulation of lipogenic, gluconeogenic, and nutrient-sensing pathways) and modulation of gut microbial community structure. The repeated observation of hepatic benefit across diet-induced and genetic models supports the potential of L. acidophilus as a probiotic candidate for further development in MASLD and diabetes-associated metabolic disease.
The abstract does not provide key experimental details needed to fully assess translational potential, including probiotic dosing regimen, duration of treatment, sample sizes, statistical outcomes, safety signals, or the specific human cohort demographics and analytic methods. Additionally, while transcriptomic and microbial changes are mentioned, the full lists of differentially expressed genes, pathways, taxa, and effect sizes are not included in the abstract. These details would be necessary to evaluate reproducibility, magnitude of effect, and clinical applicability.
In summary, based on the information reported in the abstract, Lactobacillus acidophilus supplementation produced consistent improvements in hepatic steatosis and inflammatory injury across multiple mouse models, improved glucose tolerance in ob/ob mice, modulated hepatic metabolic gene expression and nutrient-sensing pathways, and altered gut microbiota structure. Human cohort analyses showed context-dependent microbial patterns that supported the choice of this probiotic strain. Further methodological and outcome details are required to assess clinical translation and to design human interventional studies.